Characterisation Of Human Embryonic Stem Cell Differentiation To Haematopoietic Progenitors And Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$638,856.00
Summary
Blood stem cells, which are found in the bone marrow, are currently used for treating human blood disorders including leukemia and lymphoma. However, for the majority of bone marrow transplant candidates, suitable donors cannot be found. Using embryonic stem cells, this project aims to define the conditions required to generate blood stem cells in the laboratory. The aim of the work is to provide a new source of blood stem cells that could be used in place of donor derived bone marrow.
Generating Haematopoietic Stem Cells From Human Pluripotent Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$872,215.00
Summary
Blood stem cell transplantation is a vital therapy for patients with leukaemia following chemotherapy or for patients with bone marrow failure. Because many patients lack a donor, there is a need for an alternate source of stem cells. Using a new approach that we have developed, our laboratories will make blood stem cells from human pluripotent stem cells that will treat patients needing a transplant.
Characterization Of HOXA-expressing Human Haematopoietic Cells Generated From Embryonic Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$622,464.00
Summary
Blood stem cell transplants are used for treating a range of human blood disorders such as leukaemias. However, for many patients, suitable donors cannot be found. We are searching for ways in which embryonic stem cells can be turned into blood stem cells in the laboratory to provide a new source of these cells that could then be used to treat patients.
Transcriptional Regulation Of Definitive Hematopoietic Development In Humans
Funder
National Health and Medical Research Council
Funding Amount
$800,036.00
Summary
Blood stem cell transplantation is a vital therapy for patients with leukaemia following chemotherapy or for patients with bone marrow failure. Because many patients lack a donor, there is a need for an alternate source of stem cells, such as human pluripotent stem cells. During development, blood cells are formed from the blood vessel wall, or endothelium. In this project, we will study the regulation of this process in order to more efficiently make human blood cells in the laboratory.
A Suite Of Engineered Human Pluripotent Stem Cell Lines To Facilitate The Generation Of Hematopoietic Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$881,221.00
Summary
Our goal is to develop tools that address major bottlenecks that have prevented the generation of blood forming stem cells in culture for therapeutic use. We will generate human embryonic stem cell reporter lines that can be used to monitor key milestones in blood stem cell development. These lines will serve as tools to identify growth conditions to improve the differentiation of pluripotent stem cells to functional blood stem cells.
The Role Of Oligodendrocytes In Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$625,292.00
Summary
Dementia affects 35.6 million people world-wide; this number is projected to double every 20 years. Frontotemporal dementia (FTD) is the second most common type and has been found to have similar cause and pathology to common neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). We ultimately require treatments to slow, stop and repair the damaged brain of FTD patients and this is only possible by understanding the mechanisms involved in the onset and progression of disease.
Are Oligodendrocytes The Missing Link In Amyotrophic Lateral Sclerosis Pathogenesis?
Funder
National Health and Medical Research Council
Funding Amount
$1,054,405.00
Summary
Amyotrophic Lateral Sclerosis (ALS) is a debilitating and progressive neurodegenerative disease. Recent research suggests important cells of the central nervous system called glia play a role in disease onset and progression. We are interested in a type of glia called oligodendrocytes; they are crucial for supporting the survival of the cells that die in ALS. Only through understanding the underlying biology of ALS can we aim to identify effective therapies that will benefit patients.
A Simple Method To Improve Stem Cell Transplant Therapy
Funder
National Health and Medical Research Council
Funding Amount
$831,652.00
Summary
Despite the success of hematopoietic stem cell transplantation and years of promise, almost all other stem cell therapies are considered experimental and remain in preclinical or early-phase clinical testing. This study aims to improve the efficiency of stem cell transplantation by manipulating cellular metabolism prior to transplantation, if effective these results may offer hope to patients suffering from a broad range of disorders.
The Role Of Stem-progenitor Cells In Regeneration Of Mouse Endometrium.
Funder
National Health and Medical Research Council
Funding Amount
$311,938.00
Summary
The endometrium (lining of the uterus) undergoes breakdown and re-growth each month as part of the menstrual cycle. This restorative process is not well understood. For the first time stem cells have been identified within human endometrium that are likely to be responsible for its remarkable regeneration. The aim of this project is to identify stem cells within the mouse endometrium, to use as a model to understand how the endometrium restores each month after menstruation.
Understanding The Pathogenesis Of Mitochondrial Disease Using IPS Cells
Funder
National Health and Medical Research Council
Funding Amount
$640,372.00
Summary
Induced pluripotent stem (iPS) cells are stem cells derived from adult skin cells that can be converted into cell types such as neurons. iPS cells offer great promise in understanding and treating inherited disorders. However, there are concerns that the “epigenetic memory” of iPS cells has not been completely erased, which may limit the utility of iPS cells. We will evaluate and validate the use of iPS technology in mouse and human models of inherited disorders affecting energy generation.